Aminoglycosides: Clinical Use and Management
Aminoglycosides should be dosed once-daily at 5-7 mg/kg (gentamicin/tobramycin equivalent) or 15-20 mg/kg (amikacin) in patients with preserved renal function, with therapeutic drug monitoring to ensure trough concentrations remain sufficiently low to minimize nephrotoxicity. 1, 2
Primary Indications
Aminoglycosides are concentration-dependent bactericidal agents reserved for specific clinical scenarios:
- Severe sepsis and septic shock: Use in combination with broad-spectrum β-lactam antibiotics for empiric coverage of gram-negative pathogens 1
- Gram-negative bacteremia and nosocomial pneumonia: Particularly when multidrug-resistant organisms are suspected 1
- Complicated urinary tract infections due to carbapenem-resistant Enterobacteriaceae (CRE): Single-dose for simple cystitis; plazomicin 15 mg/kg IV q12h for complicated UTI 3
- Endocarditis: In combination therapy for enterococcal or staphylococcal endocarditis (gentamicin 3 mg/kg/day divided every 8 hours for 2 weeks) 4
- Complicated intra-abdominal infections: As part of combination regimens 5
Optimal Dosing Strategy
Standard Dosing (Preserved Renal Function)
The pharmacodynamic goal is to optimize peak drug concentrations, as clinical success correlates with higher peak-to-MIC ratios 1:
- Gentamicin/Tobramycin: 5-7 mg/kg once daily
- Amikacin: 15-20 mg/kg once daily
Critical principle: Once-daily dosing provides comparable or superior efficacy with potentially decreased nephrotoxicity compared to multiple daily dosing 1, 2. This approach takes advantage of concentration-dependent killing, prolonged post-antibiotic effect, and minimizes adaptive bacterial resistance 6.
Renal Impairment Adjustments
- Mild chronic renal impairment: Give full once-daily equivalent dose but extend the interval between doses (up to 3 days) 1
- Severe renal dysfunction: Do not use once-daily dosing if the aminoglycoside cannot clear within several days; consult infectious disease specialist 1
- Loading dose: Always give full loading dose regardless of renal function, as it is not affected by renal impairment (though maintenance dosing and frequency are) 1
Special Populations
- Critically ill patients with sepsis: Use actual body weight for initial dosing due to expanded extracellular volume from fluid resuscitation 1
- Lean body weight: Recent guidelines recommend dosing based on lean body weight in adults 7
Therapeutic Drug Monitoring
Monitor trough concentrations primarily to minimize nephrotoxicity risk, not to ensure efficacy 1, 2. The goal is to ensure trough levels are sufficiently low before the next dose.
Monitoring Strategy
- When to monitor: If therapy expected to continue beyond 48 hours 7
- Preferred method: Area under the concentration-time curve (AUC) monitoring in adults 7
- Traditional approach: Trough concentrations should be low (gentamicin <1 µg/mL) 4
- Frequency: Minimum weekly monitoring of concentrations 8
Exception: Endocarditis
For enterococcal endocarditis, use divided daily dosing (every 8 hours), not once-daily dosing, as animal model data for once-daily dosing in endocarditis are conflicting 4. Target gentamicin peak of 3 µg/mL and trough of <1 µg/mL 4.
Contraindications and Major Cautions
Absolute Contraindication
MT-RNR1 genetic variants (m.1095T>C, m.1494C>T, m.1555A>G): These variants increase risk of permanent aminoglycoside-induced hearing loss. Avoid aminoglycosides unless infection severity outweighs the high risk of permanent hearing loss and no safe alternatives exist 9.
Relative Contraindications
- Severe baseline renal dysfunction: Where drug clearance would take several days 1
- Pregnancy: Use only when benefits clearly outweigh risks; in utero exposure can cause permanent ototoxicity 10. For pregnant patients with severe infection, consider aminoglycosides with combination therapy if needed 1
- Pre-existing hearing loss or vestibular dysfunction: Ototoxicity is typically irreversible 10
Toxicity Profile and Monitoring
Nephrotoxicity
- Mechanism: Drug accumulation in proximal tubule cells causing lysosomal dysfunction 10
- Reversibility: Typically reversible with drug discontinuation 10
- Risk reduction: Once-daily dosing provides longer time until nephrotoxicity threshold is reached 6
Ototoxicity
- Mechanism: Reactive oxygen species damage to mitochondria in cochlear and vestibular hair cells, causing cell death 10
- Irreversibility: Permanent hearing loss and vestibular dysfunction 10
- No dosing advantage: No regimen appears less ototoxic than another 6
Recommended Surveillance
- Baseline and post-treatment audiometry: Should be routine practice 11
- Renal function monitoring: Assess at baseline and during therapy 11
- Systematic surveillance: Include adverse events in hospital patient safety monitoring 11
Drug Selection for Multidrug-Resistant Organisms
Amikacin is generally more active against ESBL-producing and quinolone-resistant Enterobacteriaceae than gentamicin or tobramycin, making it the preferred choice for suspected multidrug-resistant infections 11. Local resistance patterns should guide first-line aminoglycoside selection 11.
Duration of Therapy
- Sepsis/serious infections: Typically 3-5 days as part of combination therapy, de-escalate once susceptibilities known 1
- Endocarditis: 2 weeks for gentamicin component in combination regimens 4
- Complicated intra-abdominal infections: 4-7 days unless source control is difficult 5
Critical Pitfalls to Avoid
Underdosing in sepsis: Failure to achieve adequate peak concentrations on initial dosing is associated with clinical failure 1. Always use full loading doses.
Using once-daily dosing for endocarditis: This is not validated; use divided daily dosing 4.
Continuing therapy without monitoring: Monitor drug levels if treatment extends beyond 48 hours 7.
Ignoring volume of distribution changes: Critically ill patients with fluid resuscitation have expanded extracellular volume requiring higher initial doses 1.
Prolonged monotherapy: Aminoglycosides are typically used in combination with β-lactams for synergy and to prevent resistance 1, 11.